|
Volumn 25, Issue 5, 2001, Pages 309-318
|
The performance and problems of the Turkish pharmaceutical industry: Is there a need to develop a national drug policy
a |
Author keywords
national drug policy; Turkish pharmaceutical sector
|
Indexed keywords
ANALGESIC AGENT;
ANTACID AGENT;
ANTIANEMIC AGENT;
ANTIASTHMATIC AGENT;
ANTIBIOTIC AGENT;
ANTIDIARRHEAL AGENT;
ANTIEMETIC AGENT;
ANTIHISTAMINIC AGENT;
ANTIHYPERTENSIVE AGENT;
ANTIMIGRAINE AGENT;
ANTIPARASITIC AGENT;
ANTIRHEUMATIC AGENT;
ANTITUSSIVE AGENT;
CARDIOVASCULAR AGENT;
DERMATOLOGICAL AGENT;
DIURETIC AGENT;
HORMONE;
HYPNOTIC AGENT;
LAXATIVE;
MUSCLE RELAXANT AGENT;
SPASMOLYTIC AGENT;
TRANQUILIZER;
VITAMIN;
ESSENTIAL DRUG;
COST BENEFIT ANALYSIS;
DRUG COST;
DRUG INDUSTRY;
DRUG MANUFACTURE;
DRUG USE;
FINANCIAL MANAGEMENT;
HEALTH CARE POLICY;
PERFORMANCE;
REVIEW;
ARTICLE;
DEVELOPING COUNTRY;
DRUG LEGISLATION;
ECONOMICS;
GOVERNMENT;
HEALTH CARE DELIVERY;
HUMAN;
LEGAL ASPECT;
TURKEY (REPUBLIC);
DEVELOPING COUNTRIES;
DRUG COSTS;
DRUG INDUSTRY;
DRUGS, ESSENTIAL;
FINANCING, GOVERNMENT;
GOVERNMENT AGENCIES;
HEALTH POLICY;
HEALTH SERVICES ACCESSIBILITY;
HUMANS;
LEGISLATION, DRUG;
TURKEY;
|
EID: 0035486827
PISSN: 01485598
EISSN: None
Source Type: Journal
DOI: 10.1023/A:1010685207582 Document Type: Review |
Times cited : (9)
|
References (11)
|